BR112012020585A2 - composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase - Google Patents
composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinaseInfo
- Publication number
- BR112012020585A2 BR112012020585A2 BR112012020585A BR112012020585A BR112012020585A2 BR 112012020585 A2 BR112012020585 A2 BR 112012020585A2 BR 112012020585 A BR112012020585 A BR 112012020585A BR 112012020585 A BR112012020585 A BR 112012020585A BR 112012020585 A2 BR112012020585 A2 BR 112012020585A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- compound
- pharmaceutical composition
- tyrosine kinase
- mediated disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30774210P | 2010-02-24 | 2010-02-24 | |
| PCT/US2011/025368 WO2011106248A2 (en) | 2010-02-24 | 2011-02-18 | Trimethoxyphenyl inhibitors of tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012020585A2 true BR112012020585A2 (pt) | 2018-04-17 |
Family
ID=44476668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012020585A BR112012020585A2 (pt) | 2010-02-24 | 2011-02-18 | composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110206661A1 (pt) |
| EP (1) | EP2539347A2 (pt) |
| JP (1) | JP2013520501A (pt) |
| KR (1) | KR20120120970A (pt) |
| CN (1) | CN102892770A (pt) |
| AU (1) | AU2011218805A1 (pt) |
| BR (1) | BR112012020585A2 (pt) |
| CA (1) | CA2790199A1 (pt) |
| WO (1) | WO2011106248A2 (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009303758B8 (en) | 2008-09-18 | 2015-02-19 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US20110195066A1 (en) * | 2010-02-05 | 2011-08-11 | Auspex Pharmaceuticals, Inc. | Quinoline inhibitors of tyrosine kinase |
| US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| AU2013280644B2 (en) | 2012-06-26 | 2018-08-02 | Jeffrey A. BACHA | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| AU2013318182C1 (en) | 2012-09-18 | 2022-01-20 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| MX369956B (es) | 2013-12-03 | 2019-11-27 | Auspex Pharmaceuticals Inc | Metodos para preparar compuestos de benzoquinolina. |
| WO2015120110A2 (en) | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
| US20150284327A1 (en) * | 2014-04-04 | 2015-10-08 | Auspex Pharmaceuticals, Inc. | Oxindole inhibitors of tyrosine kinase |
| IL305352A (en) | 2015-03-06 | 2023-10-01 | Auspex Pharmaceuticals Inc | Methods for treating abnormal movement disorders |
| WO2017223433A1 (en) * | 2016-06-24 | 2017-12-28 | Ohio State Innovation Foundation | Methods and compositions for the treatment of cancer |
| WO2022111390A1 (zh) * | 2020-11-24 | 2022-06-02 | 广州君赫生物科技有限公司 | 化合物在制备调降 runx2 表达试剂中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| ATE451381T1 (de) * | 2005-01-19 | 2009-12-15 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| CA2624179A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| DK2078026T3 (da) * | 2006-11-21 | 2012-04-30 | Rigel Pharmaceuticals Inc | Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf |
| MY169761A (en) * | 2007-11-07 | 2019-05-15 | Rigel Pharmaceuticals Inc | Wet granulation using a water sequestering agent |
| UA108077C2 (xx) * | 2009-07-02 | 2015-03-25 | Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну | |
| CA2768368A1 (en) * | 2009-07-17 | 2011-01-20 | Rigel Pharmaceuticals, Inc. | Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
-
2011
- 2011-02-18 JP JP2012555051A patent/JP2013520501A/ja not_active Withdrawn
- 2011-02-18 US US13/030,256 patent/US20110206661A1/en not_active Abandoned
- 2011-02-18 BR BR112012020585A patent/BR112012020585A2/pt not_active IP Right Cessation
- 2011-02-18 CA CA2790199A patent/CA2790199A1/en not_active Abandoned
- 2011-02-18 WO PCT/US2011/025368 patent/WO2011106248A2/en active Application Filing
- 2011-02-18 AU AU2011218805A patent/AU2011218805A1/en not_active Abandoned
- 2011-02-18 KR KR1020127024828A patent/KR20120120970A/ko not_active Application Discontinuation
- 2011-02-18 CN CN2011800111808A patent/CN102892770A/zh active Pending
- 2011-02-18 EP EP11747896A patent/EP2539347A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20110206661A1 (en) | 2011-08-25 |
| WO2011106248A3 (en) | 2012-01-05 |
| JP2013520501A (ja) | 2013-06-06 |
| AU2011218805A1 (en) | 2012-08-30 |
| KR20120120970A (ko) | 2012-11-02 |
| EP2539347A2 (en) | 2013-01-02 |
| WO2011106248A2 (en) | 2011-09-01 |
| CN102892770A (zh) | 2013-01-23 |
| CA2790199A1 (en) | 2011-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012020585A2 (pt) | composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase | |
| BR112013031819A2 (pt) | suporte polimérico, composição farmacêutica, composto, métodos de tratar um distúrbio, e, de preparar um suporte | |
| BR112014010197A2 (pt) | composto, composição farmacêutica, método de tratamento de um distúrbio | |
| BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
| BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
| BR112014008126A2 (pt) | composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção | |
| BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
| BR112014007203A2 (pt) | composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção | |
| BRPI1008869A2 (pt) | nanopartícula, composto, composição farmacêutica, método para tratar câncer ou metástase, e, método de liberação prolongada de um composto de platina | |
| BRPI0913518A2 (pt) | composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune | |
| BR112013012309A2 (pt) | composto, composição, métodos de tratamento e usos de um composto | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BR112013014692A2 (pt) | composto e respectivo processo de preparação e composição farmacêutica | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| IL225597A0 (en) | Pharmaceutical preparation, methods of treatment and its uses | |
| PL2672966T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
| BR112014032053A2 (pt) | composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção | |
| BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
| BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
| HUE054621T2 (hu) | Gyógyászáti készítmény, kezelési eljárások és alkalmazásaik | |
| BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| BR112013006232A2 (pt) | processo de tratamento cosmético, composto e composição cosmética | |
| BR112015007214A8 (pt) | composto, método para a inibição da atividade da quinase, método para o tratamento, composição, utilização de um composto e invenção | |
| BR112014031899A8 (pt) | composto, composição farmacêutica, e, método para tratamento de um distúrbio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |